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Targeting of B and T lymphocyte associated
(BTLA) prevents graft-versus-host disease
without global immunosuppression
Jörn C. Albring,1,2 Michelle M. Sandau,1 Aaron S. Rapaport,1
Brian T. Edelson,1 Ansuman Satpathy,1 Mona Mashayekhi,1
Stephanie K. Lathrop,3 Chyi-Song Hsieh,3 Matthias Stelljes,4
Marco Colonna,1 Theresa L. Murphy,1 and Kenneth M. Murphy1,2
of Pathology and Immunology, 2Howard Hughes Medical Institute, and 3Department of Medicine,
Division of Rheumatology, Washington University School of Medicine, St. Louis, MO 63110
4Department of Medicine/Hematology and Oncology, University of Muenster, 48149 Muenster, Germany

Graft-versus-host disease (GVHD) causes significant morbidity and mortality in allogeneic
hematopoietic stem cell transplantation (aHSCT), preventing its broader application to
non–life-threatening diseases. We show that a single administration of a nondepleting
monoclonal antibody specific for the coinhibitory immunoglobulin receptor, B and
T lymphocyte associated (BTLA), permanently prevented GVHD when administered at the
time of aHSCT. Once GVHD was established, anti-BTLA treatment was unable to reverse
disease, suggesting that its mechanism occurs early after aHSCT. Anti-BTLA treatment
prevented GVHD independently of its ligand, the costimulatory tumor necrosis factor receptor
herpesvirus entry mediator (HVEM), and required BTLA expression by donor-derived T cells.
Furthermore, anti-BTLA treatment led to the relative inhibition of CD4+ forkhead box
P3 (Foxp3) effector T cell (T eff cell) expansion compared with precommitted naturally
occurring donor-derived CD4+ Foxp3+ regulatory T cell (T reg cell) and allowed for graftversus-tumor (GVT) effects as well as robust responses to pathogens. These results suggest
that BTLA agonism rebalances T cell expansion in lymphopenic hosts after aHSCT, thereby
preventing GVHD without global immunosuppression. Thus, targeting BTLA with a monoclonal antibody at the initiation of aHSCT therapy might reduce limitations imposed by histocompatibility and allow broader application to treatment of non–life-threatening diseases.
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Replacement of an abnormal lymphohemato
poietic system by allogeneic hematopoietic stem
cell transplantation (aHSCT) from a healthy
donor is an effective treatment for many dis
orders of the hematopoietic system (Sykes and
Nikolic, 2005; Copelan, 2006). Induction of a
mixed hematopoietic donor-host chimerism
can induce long-lasting tolerance to foreign tis
sues without the need for life-long immuno
suppressive therapy (Kawai et al., 2008). aHSCT
therapy has been improved by better donor
identification (Petersdorf et al., 2004), more
tolerable conditioning regimens (McSweeney
et al., 2001), and enhanced supportive care.
However, significant treatment-related morbidity
and mortality from chemotherapy, radiotherapy,
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infections, and graft-versus-host disease (GVHD)
remain significant clinical problems. Therefore,
aHSCT is commonly indicated only for treat
ment of conditions where other treatment op
tions are far inferior or lacking.
Costimulatory molecules of the CD28 and
TNF families regulate GVHD, with inhibitory
and activating receptors either decreasing or in
creasing its severity (Tamada et al., 2000; Blazar
et al., 2003; Xu et al., 2007). B and T lympho
cyte associated (BTLA) is an inhibitory immu
noglobulin superfamily receptor, whose ligand
is the TNF receptor herpesvirus entry mediator
© 2010 Albring et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months it
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(HVEM) and which has only been examined in a nonirradi
ated model of chronic allostimulation without classical GVHD
where donor cells lacking BTLA failed to persist (Hurchla
et al., 2007). The role of BTLA in aHSCT using irradiated
recipients, in which clinical symptoms and pathology similar
to human GVHD develop, has not been examined.

Figure 1. Anti-BTLA treatment permanently prevents GVHD. (a) Lethally irradiated CB6F1 mice received BMC and splenocytes from C57BL/6 WT
(closed squares, n = 5) or BTLA/ (open squares, n = 5) donors. (b) Lethally irradiated CB6F1 mice received BMC and splenocytes from syngeneic donors
(closed squares, n = 10), C57BL/6 mice and antibodies PIP (open circles, n = 15), or 6A6 (closed circles, n = 15). Shown are cumulative data from three
independent experiments. (c) Lethally irradiated CB6F1 mice received BMC and splenocytes from C57BL/6 mice plus control antibody PIP (open circles,
n = 5) or 6A6 (closed circles, n = 5) on the day of BMT or 6A6 14 d after BMT (open squares, n = 5). (d) Lethally irradiated CB6F1 mice received BMC and
splenocytes from C57BL/6 HVEM/ mice and control antibody PIP (open circles, n = 5) or 6A6 (closed circles, n = 5). (e) Lethally irradiated BALB/c mice
received TCD-BM alone (green lines and closed squares, n = 10) or in combination with splenocytes from C57BL/6 mice and control antibody PIP (red lines
and open circles, n = 10) or 6A6 (blue lines and closed circles, n = 10) on the day of BMT. Shown are cumulative data from two independent experiments.
Weight and clinical score data shown are mean ± SD. Data are representative of two independent experiments with five mice per group or cumulative
data from independent experiments as indicated. P-values of >0.05 are considered not significant (n.s). ***, P < 0.001.
2552
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RESULTS AND DISCUSSION
To determine the role of BTLA in the development of
GVHD, we first examined WT and BTLA/ donor mice
(Watanabe et al., 2003) using a nonlethal parent-into-irradiated
F1 model of aHSCT (Stelljes et al., 2008). In this model,
GVHD results from partial MHC mismatch between H-2b
haplotype donor cells and lethally irradiated H-2b/d haplotype
recipients. BM and splenocytes from WT or BTLA/ mice
on the C57BL/6 background were transferred into lethally
irradiated CB6F1 recipients (Fig. 1 a). Transplantation of
WT donor cells into CB6F1 recipients caused body weight
loss of 30% and clinical scores (Cooke et al., 1996) of 3
that persisted for >40 d. BTLA/ and WT donor cells
caused similar GVHD, suggesting that BTLA does not nor
mally regulate GVHD in this model. To test whether BTLA

expressed by recipient mice might regulate GVHD in this
model, we used BTLA/ CB6F1 hosts as recipients of BTLA/
BM and splenocytes (Fig. S1 a). BTLA/ donor cells induced
similar GVHD in BTLA+/ and BTLA/ hosts, which is
comparable to GVHD by WT donor cells (Fig. 1 a). Col
lectively, these data suggest that BTLA does not normally regu
late GVHD.
Because BTLA generates inhibitory signals and functions
in autoimmunity (Watanabe et al., 2003), malaria infection
(Lepenies et al., 2007), and intestinal inflammation (Steinberg
et al., 2008), we wondered whether harnessing the inhibitory
effects of BTLA on the immune response by forced engage
ment would attenuate GVHD. To test this, we compared the
effects of an agonistic nondepleting anti-BTLA monoclonal
antibody (Hurchla et al., 2005; Lepenies et al., 2007), 6A6,
administered at the time of aHSCT (Fig. 1 b) with an iso
type control antibody, PIP, that recognizes bacterial GST
(Gronowski et al., 1999). Mice treated with PIP showed sim
ilar progression of GVHD (Fig. 1, a and b), with clinical
scores between 3 and 4 persisting for >140 d (Fig. S1 b).
GVHD was associated with thickening of the lamina propria
and muscularis, with severe inflammation and ulceration of
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within 30 d after aHSCT from severe GVHD (Fig. 1 e, right).
Although mice that received the anti-BTLA treatment were
not fully protected from GVHD, with clinical scores ranging
from 1 to 3 (Fig. 1 e, middle) and slightly more weight loss than
the control group that had received T cell–depleted BM cells
(BMCs [TCD-BMs]) alone (Fig. 1 e, left), 70% of recipients
treated with 6A6 survived for >200 d after aHSCT.
Although the precise molecular targets of BTLA signaling
are still obscure (Gavrieli and Murphy, 2006; Wu et al.,
2007), BTLA engagement by HVEM can inhibit T cell pro
liferation in vitro (Sedy et al., 2005) and promote tolerance
induction in vivo (Liu et al., 2009). Therefore, we asked if
anti-BTLA treatment alters donor T cell proliferation or IL-2
production in vivo. CFSE-labeled donor splenocytes were
transferred into CB6F1 recipients that were treated with PIP,
6A6, or 6F7. Donor T cell proliferation was assessed after
aHSCT and, by 3 d after aHSCT, reduced CFSE levels sug
gested that proliferation had occurred (Fig. 2 e). CD4+
T cells had reduced proliferation after treatment with 6A6
and 6F7 antibodies 3 d after aHSCT (Fig. 2 e, middle), and the
total accumulation of donor CD4+ T cells was significantly
reduced compared with control (P < 0.0018 and P < 0.0083;
Fig. 2 b). In contrast, CD8+ T cell proliferation and accu
mulation were not significantly affected by 6A6 treatment
(P < 0.8489; Fig. 2, a and e, left). As 6F7 treatment leads to
partial depletion of cells, we also assessed the level of annexin
V binding, which is an indicator of early apoptosis. Mice
treated with 6F7, but not PIP or 6A6, showed increased bind
ing of annexin V on CD4+ and CD8+ T cells 7 d after aHSCT,
which was not observed on day 3 (Fig. S1 g).
Although accumulation of CD4+ T cells was lower in 6A6treated than in PIP-treated mice, the production of IL-2 7 d
after aHSCT was not statistically different (Fig. S2, a and b).
A small but significant reduction in IFN- and IL-4, but not
IL-17, production was observed in 6A6-treated mice com
pared with controls (Fig. S2, a and b). In summary, 6A6 ad
ministered at the time of aHSCT reduced the proliferation
and accumulation of donor-derived CD4+Foxp3 effector
T cells (T eff cells) without inducing anergy, inhibiting IL-2
production or causing major alterations in cytokines.
These effects were suggestive of the actions of CD4+
Foxp3+ regulatory T cells (T reg cells) expressing the tran
scription factor forkhead box P3 (Foxp3; Hori et al., 2003).
T reg cells have recently been reported to play a significant
role in regulating GVHD (Taylor et al., 2002; Edinger et al.,
2003b), and there are ongoing clinical trials aimed directly at
the use of T reg cells as an intervention in human GVHD
(NCI clinical trial NCT00725062).
To determine whether 6A6 treatment influences T reg
cells, we measured the accumulation and proliferation of
donor-derived T eff cells after aHSCT (Fig. 2, c and e, right).
In PIP-treated recipients that developed GVHD, significantly
fewer T reg cell were detected 7 d (P < 0.0393) after aHSCT
when compared with recipients that received either antiBTLA treatment 6A6 or 6F7 (Fig. 2 c). Therefore, antiBTLA treatment inhibits the proliferation of T eff cells yet
2553
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the colon (Stelljes et al., 2008; Fig. S1 c, bottom). In contrast,
a single treatment of 10 µg/g body weight of 6A6, given at
the time of aHSCT, prevented GVHD completely, with weight
loss and GVHD similar to the syngeneic control group (Fig. 1 b)
for 140 d after aHSCT (Fig. S1 b). Furthermore, 6A6-treated
mice had no histological evidence of GVHD in the colon
(Fig. S1 c, top). Thus, a single administration of anti-BTLA
antibody eliminates weight loss, histological changes, and
clinical signs of GVHD.
We next asked if 6A6 acted by simply depleting donor cells
that express BTLA. As a positive control, we included a de
pleting murine anti-BTLA antibody, 6F7 (Hurchla et al., 2005;
Truong et al., 2009). CFSE-labeled donor cells were trans
ferred into WT recipients that also received PIP, 6A6, or 6F7
antibody. 2 d after transfer, we found similar numbers of
CFSE+ cells in mice that received either PIP or 6A6 antibody
(Fig. S1 d, left) and no significant differences between numbers
of CD19+, CD4+, or CD8+ lymphocytes (Fig. S1 d, right).
Treatment with 6F7 caused a significant depletion of CFSE+
lymphocytes, particularly from the CD19+ cell population
(Fig. S1 d). Furthermore, surface-bound 6A6 was detectable on
live donor-derived cells in vivo up to 7 d after transfer (Fig. S1 e).
In addition, 6A6 treatment was unable to prevent GVHD
caused when BTLA/ donors were used as a source of BM
for aHSCT (Fig. S1 f). Thus, 6A6 does not deplete lympho
cytes (Hurchla et al., 2007; Lepenies et al., 2007) but requires
the expression of BTLA on donor cells to prevent GVHD.
Next, we asked if 6A6 could reverse established GVHD.
We compared immediate with delayed administration of
6A6 (Fig. 1 c). Again, immediate 6A6 administration pre
vented GVHD. In contrast, there was no statistical difference in
weight loss or clinical scores between mice that received 6A6
14 d after aHSCT and with mice that received PIP (Fig. 1 c).
6A6 binds to a region of BTLA that is involved in inter
actions with HVEM (Hurchla et al., 2005). Thus, 6A6 might
prevent GVHD by preventing HVEM and BTLA interac
tions, thus blocking costimulatory signaling to donor cells
(Xu et al., 2007). Although our data indicated that host
BTLA is not involved (Fig. S1 a), we wished to test this pos
sibility independently. Transfer of HVEM/ donor cells
caused induction of GVHD when administered with PIP
(Fig. 1 d). The severity of GVHD caused by HVEM/
donor cells was somewhat less than that caused by WT donor
cells (Fig. 1 b), consistent with a study which found that
HVEM and LIGHT are costimulatory in promoting GVHD
(Xu et al., 2007). However, 6A6 also prevented GVHD
caused by HVEM/ donor cells (Fig. 1 d). These results in
dicate that 6A6 prevents GVHD in a manner that is indepen
dent of HVEM, suggesting it acts directly through BTLA.
Because the parent-into-irradiated F1 model of aHSCT
does not result in lethal GVHD, we wished to test the potency
of the anti-BTLA treatment in a model of complete MHC
mismatch (H-2b into H-2d) that results in lethal GVHD in un
treated mice (Lu et al., 2001; Edinger et al., 2003b). Control
mice developed severe GVHD with pronounced weight loss
and clinical scores of >6 (Fig. 1 e, left and middle) and died
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allows the accumulation of T reg cells, resulting in an in
creased T reg/T eff cell ratio (P > 0.0028; Fig. 2 d). This re
sult is in agreement with the demonstration that T reg cells
maintain low levels of BTLA after activation, in contrast to
conventional T cells which up-regulate BTLA expression
upon activation (Fig. S2 c; Hurchla et al., 2005). Thus, 6A6
treatment increases the numbers and the frequency of donorderived T reg cells after aHSCT.
6A6 treatment could increase T reg cell frequency either by
inducing Foxp3 expression in naive donor CD4+ T cells (Chen
et al., 2003) or by causing in vivo expansion of preexisting
donor T reg cells relative to T eff cells. To distinguish these alter
natives, we used B6.Foxp3gfp reporter mice (Fontenot et al.,
2005). We performed mixed aHSCT with WT and Foxp3gfp
2554

mice as donors, using purified GFP-negative cells
from Foxp3gfp mice to remove preexisting T reg
cells from the donor population. In this mixed
aHSCT setting, 6A6 treatment similarly de
creased the accumulation of T eff cells in both
populations, but T reg cells expanded only from
preexisting T reg cells (Fig. 2, f and g; and Fig. S2,
e and f). Therefore, the donor T reg/T eff cell
ratio increased only among the WT donor
T cells and not in the Foxp3gfp donor T cells, as
assessed by intracellular staining for endogenous
Foxp3 (Fig. 2 f and Fig. S2 g). In addition, donorderived CD4+ T cells, which were originally
isolated from B6.Foxp3gfp mice as negative for
GFP expression, remained negative for Foxp3 as
assessed by the Foxp3-GFP reporter (Fig. S2 e, right).
To further characterize the conditions necessary for the
expansion of T reg cells, we evaluated what effects antiBTLA treatment had on T reg cells in the steady state and
whether the presence of alloantigen or HVEM on host tissue
is required. When unmanipulated B6.Foxp3gfp mice received
6A6, the frequency of T eff cells, T reg cells, or the resulting
ratio did not change (Fig. S3, a–d). Similarly, although syn
geneic aHSCT of CB6F1 resulted in a small decrease of T eff
cells 7 d after transplant, no major accumulation of T reg cells
and no increased T reg/T eff cell ratio was observed (Fig. S3,
e–h). When HVEM/ donors and MHC-mismatched
HVEM/ recipients were used, the ratio of T reg/T eff
cells increased by inhibiting the accumulation of T eff cells
Anti-BTLA prevents graft-versus-host disease | Albring et al.
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Figure 2. Anti-BTLA treatment allows for the expansion of preexisting donor-derived T reg cells by
inhibiting T eff cell proliferation. (a–e) Lethally irradiated CB6F1 mice received a CFSE-labeled graft from B6.SJL
donors and were treated with control antibody PIP (open
circles), 6A6 (closed circles), or 6F7 (closed squares; n = 3
per group). The number of CD8+ T cells (a), CD4+Foxp3 (b),
and CD4+ Foxp3+ (c) was calculated from absolute numbers of live splenocytes, and the percentage of the lymphocyte population was assayed by flow cytometry. (d) The
ratio of total CD4+Foxp3+/CD4+Foxp3 cells was calculated
at the indicated time points by dividing the number
of T reg cells in c by the number of T eff cells in b. (e) CFSE
intensity of CD8+, CD4+Foxp3, and CD4+Foxp3+, 3 d after
aHSCT with PIP, 6A6, or 6F7 treatment. (f and g) Lethally
irradiated CB6F1 mice received aHSCT from B6.SJL mice
along with purified CD4+ Foxp3-negative T cells from
B6.Foxp3gfp mice with control antibody (PIP) or 6A6
(n = 5 per group). After 7 d, splenocytes were assayed by
flow cytometry to determine the relative frequency of
CD4+Foxp3+ cells among CD4+ cells (f) or the absolute
number of CD4+Foxp3+ T reg cells (g). Statistical comparisons in a–d are between the PIP- and 6A6-treated groups
at the indicated time point, and the data are displayed as
mean ± SEM. Shown are representative data from two
independent experiments with three to five mice per
group. P-values of >0.05 are considered not significant
(n.s). *, 0.01 < P < 0.05; **, 0.001 < P < 0.01.
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(Fig. S3, i–l) as observed before (Fig. 2, d and g). Collec
tively, these results suggest that 6A6 has no effect in the steady
state, does not involve HVEM, and requires allostimulation
to increase the T reg/T eff cell ratio.
Because BTLA is expressed on both T eff and T reg cells,
we tested whether the increased T reg/T eff cell ratio was the
result of a decrease in T eff cell expansion, an increased pro
liferation of T reg cells, or both by performing a mixed
aHSCT using congenically marked WT BTLA+/+ and BTLA/
donors. In this setting, the frequency of T reg cell within the
JEM VOL. 207, November 22, 2010

CD4+BTLA/ population did not change in the presence of
6A6 (7.9 ± 2 vs. 7.3 ± 2%; Fig. 3, a and c), whereas the T reg
cell frequency within the CD4+ WT population increased
more than threefold in the presence of 6A6 (48 ± 10 vs. 14.4 ±
5.5%; Fig. 3, a and b).
Importantly, 6A6 treatment decreased T eff cell numbers
more than fivefold from 2.6 × 105 ± 4.6 × 104 cells in the
control group to 3.9 × 104 ± 1.4 × 104 (P < 0.0001; Fig. 3 d),
indicating that WT-BTLA+/+ T eff cells are the main target
of the anti-BTLA treatment. WT and BTLA/ T reg cells
2555
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Figure 3. Direct engagement of BTLA on T eff cells leads to an increased frequency of CD4+Foxp3+ cells. Lethally irradiated CB6F1 mice received a 1:1 mixed aHSCT with WT-B6.SJL and B6 BTLA/ donor cells (a–e) with either control antibody (PIP) or 6A6 (n = 5 per group). After 7 d, splenocytes were analyzed by flow cytometry. (a) Shown are FACS plots to identify donor cells as H-2Kd and CD4+ (left). Intracellular Foxp3 was detected
among CD4+ T cells (right) gated on WT-B6.SJL (CD4+CD45.1+ H-2Kd) or B6 BTLA+/+ (CD4+CD45.1 H-2Kd) donor cell populations as indicated. Numbers
represent the percentage of cells within the indicated gates. The ratios of the number of WT T reg/WT T eff cells (b) and KO T reg/ KO T eff cells (c) are
shown, as well as the total number of T eff cells (d) and T reg cells (e) from the indicated donors after treatment with control antibody (PIP, open bars) or
6A6 (closed bars). (f and g) Lethally irradiated BALB/c mice received a 1:1 mixture of purified WT-B6.SJL and BTLA/ CD4+ cells and T reg cells from B6.
Foxp3gfp mice, with either control antibody PIP or 6A6 (n = 3–4 per group). After 7 d, splenocytes were analyzed by flow cytometry to determine the ratio
of WT T reg/WT T eff cells (f) or WT T reg/BTLA/ T eff cells (g). Data are displayed as mean ± SEM. Shown are representative data from two independent
experiments. (h–j) Recipient BALB/c mice received TCD-BM and splenocytes from T reg cell ablated or unmanipulated Foxp3DTR mice and PIP or 6A6 as
indicated. Survival curves (h), weight curves (i), and clinical scores (j) are shown for 6A6-treated mice that received a graft from either untreated (no DT)
Foxp3DTR donors (dashed line or filled squares; n = 5) or a graft from DT-treated (T reg depl.) Foxp3DTR donors (solid line or filled circles; n = 5) and PIPtreated mice that received a graft from DT-treated or untreated (T reg depl. and no DT) Foxp3DTR donors (dotted line or open circles; n = 10). Data are
shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
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do not expand significantly in the presence of BTLA/ T eff
cells (Fig. 3 e), confirming our observation that T reg cells
expand only when T eff cells express BTLA and are inhibited
by 6A6. To exclude any indirect effects on host tissues, we
cotransferred purified populations of WT T reg cells together
with WT or BTLA/ T eff cells into BALB/c recipients,
which express an allele of BTLA not recognized by 6A6 (Fig. 3,
f and g; and Fig. S4; Hurchla et al., 2005). The WT T reg/
WT T eff cell ratio increased after 6A6 treatement (P < 0.0004;
Fig. 3 f) as observed before (Fig. 2 g and Fig. 3 b). In contrast,
when BTLA/ T eff cells were present the WT T reg/
BTLA/ T eff cell ratio did not increase (Fig. 3 g), indicat
ing that the expansion of T reg cells is caused by 6A6 reduc
ing the expansion of T eff cells. In this setting, the WT
2556

T reg/BTLA/ T eff cell ratio even decreased (Fig. 3 g and
Fig. S4 i), suggesting that low expression levels of BTLA on
T reg cells inhibits their expansion when proliferation of
BTLA/ T eff cells is not restricted.
To ask whether the inhibition of T eff cells had an effect
on GVHD in the absence of T reg cells, we used C57BL/6
Foxp3DTR mice as donors in the lethal model of GVHD. Pre
treatment with diphtheria toxin reduced T reg cells by >95%
in Foxp3DTR donors. 90% of control animals died within 14 d
of aHSCT, irrespective of whether or not the BM graft con
tained T reg cells (Fig. 3 h). All mice that were treated with the
6A6 antibody survived beyond day 70 (Fig. 3 h). Mice that re
ceived a graft with T reg cells and 6A6 eventually recovered
to 90% of their starting weight (Fig. 3 i) and developed
Anti-BTLA prevents graft-versus-host disease | Albring et al.
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Figure 4. Anti-BTLA treatment does not lead to global immunosuppression. (a) Representative images of A20-Luc tumor cell localization 7 d (left)
and 15 d (right) after aHSCT in lethally irradiated BALB/c mice that had received A20-Luc lymphoma cells with TCD-BM alone (n = 10) or together with
splenocytes from C57BL/6 mice and control antibody PIP (n = 10) or 6A6 (n = 10). (b) Shown are units of photons per second for individual animals from
panel a for days 5 (n = 5), 7 (n = 5), and 15 (n = 10) after aHSCT, as well as unmanipulated BALB/c mice (day 0, n = 12) for comparison. Asterisks indicate
statistically significant differences between TCD-BM and 6A6 groups. Shown are cumulative data from two independent experiments, with each point
representing the BLI signal from an individual mouse. Horizontal lines represent the mean BLI signal. Vertical lines serve to separate experimental groups.
(c) Survival data of mice from a and from mice that received TCD-BM alone without tumor for comparison. Shown are cumulative data from two independent experiments. (d) CB6F1 BMC and splenocytes from syngeneic (green line; n = 10) or C57BL/6 donors and antibodies PIP (red line; n = 10) or 6A6
(blue line; n = 10) were infected with MCMV 4 wk after aHSCT and were monitored for survival. PIP-treated uninfected mice (orange line, n = 10) served
as controls. Shown are cumulative data from two independent experiments. Data are shown as mean ± SD from two independent experiments. P-values
of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
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cells and allowing the relative expansion of naturally occur
ring T reg cells. Once established, this new balance of T eff
cells is sufficient to prevent GVHD permanently while
allowing for intact responses to viral and bacterial pathogens,
as well as GVT effects. Thus, BTLA may represent a novel
therapeutic target in prevention of human GVHD. Increas
ing the safety of aHSCT could potentially allow its appli
cation more widely as a tolerogenic therapy in treatment of
autoimmune disorders or solid organ transplantation, for which
it is currently performed only experimentally (Sykes and Nikolic,
2005; Kawai et al., 2008).
MATERIALS AND METHODS
Mice and BM transplantation. B6.SJL-Ptprca Pep3b/BoyJ (B6.SJL),
C57BL/6, and C57BL/6 × BALB/c F1 (CB6F1) mice were obtained from The
Jackson Laboratory or bred in our facility. BTLA/ (Watanabe et al., 2003),
Hvem/ (Wang et al., 2005), Foxp3gfp (Fontenot et al., 2005), and Foxp3DTR
(Kim et al., 2007) mice were backcrossed to C57BL/6 for at least nine genera
tions. HVEM/ H2-Kb/d or H2-Kd/d were obtained by crossing HVEM/
mice on a B6 (H2-Kb/b) background to BALB/c (H2-Kd/d) mice. The resulting
HVEM+/ H2-Kd/b F1 mice were intercrossed to obtain HVEM/
H2-Kb/d or H2-Kd/d F2 recipients. Mice were 12–18 wk old and sex matched
for all experiments. Mice were bred and maintained in our specific pathogen–
free animal facility according to institutional guidelines with protocols approved
by the Animal Studies Committee of Washington University.
Cell transplantation and assessment of GVHD. Mice received trans
plants according to a standard protocol as previously described (Stelljes et al.,
2008). In brief, BMCs were harvested by flushing tibia and femurs of donor
mice. For the nonlethal parent-into-F1 model of GVHD, CB6F1 (H-2b/d)
recipients were lethally irradiated with 9 Gy total body irradiation using a
137Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 107
BMCs and 107 splenocytes from syngeneic (H-2b/d) or parental C57BL/6
donors (H-2b). For the lethal model of GVHD, BALB/c (H-2d) recipients
were lethally irradiated with 8 Gy total body irradiation using a 137Cs source
at a dose rate of 70 cGy/min and reconstituted with 2 × 107 TCD-BM
alone or an additional 107 splenocytes from allogeneic C57BL/6 donors (H-2b).
To obtain TCD-BM, cells were depleted of CD4+ and CD8+ cells by mag
netic depletion (Miltenyi Biotec) according to the manufacturer’s recom
mendation. In experiments where a T reg cell–depleted graft from Foxp3DTR
donors was used, recipients received an intraperitoneal injection of 20 µg
diphtheria toxin on the day of BMT. GVHD was monitored by calculating
the loss in total body weight. Body weights were measured before transplan
tation and three times a week after transplantation. Clinical GVHD intensity
was scored by assessing weight loss, posture, activity, fur texture, and skin
integrity (Cooke et al., 1996). Histopathologic analyses of the bowel were
performed on hematoxylin and eosin–stained tissue.
Administration of antibody. In some experiments, mice received at the time
of aHSCT, unless otherwise noted, a single intraperitoneal injection of
10–20 µg/g body weight of anti-BTLA antibodies 6A6 and 6F7, whose proper
ties we have previously published in detail (Hurchla et al., 2005). In brief, the
IgG hamster monoclonal antibody 6A6 is specific for the C57BL/6 allele of
BTLA and does not deplete BTLA-expressing cells in vivo (Hurchla et al., 2007;
Lepenies et al., 2007). The IgG1 mouse monoclonal anti-BTLA antibody 6F7
recognizes all known alleles of BTLA (Hurchla et al., 2005) and has been shown
to deplete BTLA-expressing cells in vivo. The IgG1 hamster monoclonal antiGST antibody PIP (Gronowski et al., 1999) was used as an isotype control.
Cell purification and depletion. To obtain purified populations of CD4+
Foxp3gfp-negative cells or CD4+ Foxp3gfp-positive cells in the indicated ex
periments, Foxp3gfp splenocytes were stained with CD4+ and the desired
population was purified by cell sorting on the MoFlo cytometer (Dako).
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low-grade GVHD with scores ranging from 1 to 3, as seen be
fore (Fig. 1 e). Mice that received a T reg cell–depleted graft
and 6A6, however, recovered only 70–80% of their starting
weight and had more severe GVHD scores ranging from 3 to 5
(Fig. 3 j). These data highlight that forced inhibition of T eff
cells through BTLA (Fig. 3 d) is sufficient to prevent lethality.
Nonetheless, the relative expansion of T reg cells (Fig. 3, b and f)
bears biological significance, as they are required to protect the
host from clinical GVHD (Fig. 3, i and j).
Because engagement of BTLA by 6A6 inhibited T eff cell
proliferation, we wondered whether this treatment allowed for
antigen-specific responses to tumors and pathogens. First, we
examined whether graft-versus-tumor (GVT) activity was
maintained after 6A6 treatment (Fig. 4, a–c). We used a model
of minimal residual disease after aHSCT that utilizes biolumi
nescence imaging (BLI) of luciferase-expressing A20-Luc leu
kemia cells (H-2d) in vivo (Edinger et al., 2003a). In this model,
GVT activity requires cytolytic activity of T cells to control the
tumor (Edinger et al., 2003b). Transplantation of A20-Luc leu
kemia cells with TCD-BM alone resulted in progressive tumor
growth (Fig. 4, a and b). In mice that had received a T cell–
containing graft with or without the 6A6 antibody, however,
tumor was never detectable by BLI, suggesting that GVT ef
fects were intact. Although all control mice died before day 45
of severe GVHD, 90% of 6A6-treated mice survived beyond
day 90 (Fig. 4 c). To exclude any antibody-mediated antitumor effects, we confirmed that the 6A6 antibody does not
bind to A20 cells, which was expected because of their BALB/c
origin (Fig. S2 d). To document initial tumor engraftment, we
quantified the total tumor number A20-GFP cells in the BM by
flow cytometry 7 d after aHSCT (Fig. S3 m).
We next examined immune responses to murine CMV
(MCMV; Nguyen et al., 2008) 4 wk after aHSCT. All ani
mals that had undergone syngeneic aHSCT survived for >60 d
after infection (Fig. 4 d). Of the mice in the allogeneic group
that had received the PIP antibody, 70% died within 10 d of
infection compared with 20% of the 6A6-treated mice. Thus,
although 6A6 treatment prevents GVHD, it allows for resis
tance to MCMV, unlike PIP-treated control recipients.
To test the immune response against bacterial infection,
animals were infected with the intracellular bacterium Listeria
monocytogenes. 3 d after infection, animals that had received
the PIP antibody had either higher (P = 0.0005 for liver and
P = 0.1816 for spleen) or lower L. monocytogenes organ bur
dens (P = 0.0227 for liver and P = 0.0059 for spleen; Fig. S3,
n–p), as has been described previously (Miura et al., 2000).
In contrast, anti-BTLA–treated mice controlled infection
similarly to both control groups, indicating an intact innate
immune response (Fig. S3, n–p). These preliminary results
suggest that 6A6-treated mice were similarly resistant to
L. monocytogenes infection to unmanipulated mice.
In summary, this study demonstrates that the anti-BTLA
antibody 6A6 administered at the time of aHSCT prevents
GVHD without the need for additional immunosuppressive
therapy. The mechanism of action is through direct engage
ment of BTLA on donor T cells, selectively inhibiting T eff
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Purification of C57BL/6 CD4+ and BTLA/ CD4+ cells was obtained
from splenocytes that were depleted of CD8+ and B220+ cells by magnetic
depletion (Miltenyi Biotech) according to the manufacturer’s recommenda
tion. Foxp3DTR mice received intraperitoneal injections for 2 d of 20 µg
diphtheria toxin per day before harvesting BM and splenocytes for aHSCT.

Tumor model and assessment of GVT effects. As a tumor challenge,
2 × 104 A20-Luc or A20-GFP where administered intravenously together
with the donor graft as indicated. Imaging was done as previously described
(Rehemtulla et al., 2000; Edinger et al., 2003a). In brief, d-Luciferin (Bio
synth AG) was reconstituted in 0.9% sodium chloride (Baxter) to a concen
tration of 15 mg/ml, filtered (0.2 µm), and frozen at 80°C until use. Mice
were given intraperitoneal injections at a dose of 150 mg/kg and allowed to
remain active in the cage for 5 min to allow circulation of luciferin. Using the
Xenogen IVIS 200 system (Caliper Life Sciences) with attached anesthesia
chamber, the animals were then anesthetized with 2% isoflurane for 5 min
and subsequently transferred to the imaging chamber where they continued
to receive a regulated flow of isoflurane through the manifold’s nose cones.
The Living Image software program (Caliper Life Sciences) was used to obtain
and analyze data. For all experiments, a 60-s exposure time was used. To detect
A20-GFP in the BM, single cell suspensions from both femurs were analyzed
by flow cytometry using the antibody CD19-APC (1D3; BD). Cells that ex
pressed high levels of CD19 and GFP were considered to be A20-GFP cells.
Cell lines. The BALB/c B cell lymphoma cell line A20 was obtained from the
American Type Culture Collection. To generate luciferase-expressing A20 cells
(A20-Luc), a 1995-bp HindIII–BamHI fragment from pGL4.23[luc2/minP]
vector (Promega) containing a minimal promoter, a Luc2 coding sequence,
and a SV40 late poly(A) signal was cloned into the HindIII and BamHI sites
of the pcDNA3.1+ mammalian expression vector (Invitrogen) to generate
pcDNA3.1+-Luc2. For stable transfections, 10 × 106 A20 cells/ml in complete
IMDM supplemented with 10% fetal calf serum and with 30 µg/ml PvuIlinearized pcDNA3.1+-Luc2 were electroporated at room temperature in
0.4-ml aliquots in 0.4-cm cuvettes in a Gene Pulser (Bio-Rad Laboratories) at
240 V and 960 mF. After electroporation, cells were cultured for 24 h in
IMDM supplemented with 10% fetal calf serum and then selected in the pres
ence of 800 µg/ml geneticin. To generate GFP-expressing A20 cells, a retro
viral reporter vector (Ranganath et al., 1998) was used that contains the coding
sequence of herpes simplex virus 1 thymidine kinase, followed by an internal
ribosomal entry site and GFP (HSV1-TK-IRES-GFP-RV). The retroviral
vector was packaged in Phoenix A cells. Before infection, the A20 cell line was
stimulated with 5 µg/ml LPS (Sigma-Aldrich) for 24 h. For infection, cells
were cultured in retroviral supernatant supplemented with 8 µg/ml polybrene
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Models of infectious disease. For MCMV infection, mice were infected
with Smith strain MCMV 4 wk after aHSCT. Virus preparation and admin
istration was performed as described previously (Krug et al., 2004). In brief,
a salivary gland stock of MCMV was prepared from BALB/c mice, with a
titer of 6.75 × 106 PFU/ml. Mice were infected intraperitoneally with a low
dose of virus (104 PFU/mouse) and then monitored for survival. For
L. monocytogenes infection, mice were infected intravenously with 2.5 × 104
L. monocytogenes (strain EGD; gift from E.R. Unanue, Washington Univer
sity School of Medicine, St. Louis, MO) 3 mo after aHSCT. To determine
organ L. monocytogenes burden at day 3 after infection, spleens and livers were
homogenized in PBS plus 0.05% Triton X-100. Serial dilutions of homoge
nate were plated on brain heart infusion agar, and bacterial CFUs were as
sessed after overnight growth at 37°C. Small portions of spleen and liver
were also fixed in 10% formalin and stained with hematoxylin and eosin.
Statistical analysis. A Student’s unpaired two-tailed t test with a 95% con
fidence interval was used for statistical analyses of body weight data, clinical
scores, and cell numbers. For analyses of survival data the log-rank test was
used. A Mann-Whitney unpaired two-tailed Student’s t test with a 95%
confidence interval was used for statistical analyses of bioluminescence data
in Fig. 4. Statistical analyses were done using Prism 4 (GraphPad Software,
Inc.). FACS data are expressed as means ± SEM. All other data are presented
as means ± SD. All experiments have been repeated at least once with three
to five mice per group, unless stated otherwise.
Online supplemental material. Fig. S1 demonstrates that BTLA expres
sion by recipient tissue does not promote GVHD and 6A6 antibody does not
deplete lymphocytes. Fig. S2 shows that 6A6 treatment does not lead to
donor T eff cell anergy and expands preexisting T reg cells. Fig. S3 shows that
6A6 inhibition of T eff cells and expansion of T reg cells requires allostimu
lation but not HVEM expression by donor or host. Fig. S4 shows that 6A6
alters the T reg cell/effector CD4+ T cell ratio by directly inhibiting BTLAexpressing T cells. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20102017/DC1.
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